Incidence and risk factors of micronutrient deficiency in patients with IBD and intestinal Behçet’s disease: Folate, Vitamin B12, 25-OH-vitamin D, and Ferritin

Yong Eun Park
   Inje University College of Medicine

Soo Jung Park (sjpark@yuhs.ac)
   Yonsei University College of Medicine

Jae Jun Park
   Yonsei University College of Medicine

Jae Hee Cheon
   Yonsei University College of Medicine

Taell Kim
   Yonsei University College of Medicine

Won Ho Kim
   Yonsei University College of Medicine

Research article

Keywords: Inflammatory bowel disease, intestinal Behçet’s disease, micronutrients, risk factors

DOI: https://doi.org/10.21203/rs.3.rs-77067/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Patients with inflammatory bowel disease (IBD) and intestinal Behçet's disease (BD) are vulnerable to micronutrient deficiencies due to diarrhea-related gastrointestinal loss and poor dietary intake caused by disease-related anorexia. However, few studies have investigated the incidence and risk factors for micronutrient deficiency.

Methods

We retrospectively analyzed 205 patients with IBD who underwent micronutrient examination, including folate, vitamin B12, 25-OH-vitamin D, and/or ferritin level quantification, with follow-up blood tests conducted 6 months later.

Results

Eighty patients (39.0%), who were deficient in any of the four micronutrients, were classified as the deficiency group, and the remaining 125 (61.0%) were classified as the non-deficient group. Compared to those in the non-deficiency group, patients in the deficiency group were much younger, had more Crohn's disease (CD) patients, more patients with a history of bowel operation, and significantly less 5-amino salicylic acid usage. Multivariate analysis revealed that CD and bowel operation were significant independent factors associated with micronutrient deficiency.

Conclusions

The incidence of micronutrient deficiency was high (39.0%). Factors including CD, bowel operation, and younger ages were found to be associated with higher risks of deficiency. Therefore, patients with IBD, especially young patients with CD who have undergone bowel resection surgery, need more attention paid to micronutrition.

Background

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic disease of the gastrointestinal (GI) tract associated with unclear etiology, leading to rectal bleeding, abdominal pain, and weight loss and repeated cycles of relapse and remission[1, 2]. Most patients with IBD, especially those with CD, suffer from weight loss and malnutrition during the course of the disease[3, 4], which may be related to lack of oral intake, increased nutrient requirements, increased GI loss, and intestinal resection or bypass surgery[3, 5].
Nutrients can be classified as either macronutrients or micronutrients. Macronutrients are energy-providing nutrients including carbohydrates, lipids, water, and proteins. Malnutrition can occur in cases of active, severe IBD, when macronutrients are not consumed or absorbed in sufficient quantities. Micronutrients, including minerals, vitamins, and trace elements, are often deficient in patients with mild disease activity or remission status[6, 7].

According to the European Society for Clinical Nutrition and Metabolism guidelines, patients with IBD should be regularly checked for micronutrient deficiencies and certain deficits should be adequately corrected[8]. Several studies have reported vitamin and mineral deficiencies in patients with IBD; these studies assessed their symptoms and effects on the quality of life and observed widely variable clinical significance[9–11]. Vitamins are organic compounds and are classified as either water-soluble, including thiamine (B1), riboflavin (B2), nicotinic acid/niacin (B3), pyridoxine (B6), cobalamin (B12), biotin, pantothenic acid, folic acid, and vitamin C (ascorbic acid), or fat-soluble, including vitamins A, D, E, and K[6]. Dietary minerals are important inorganic components that work as cofactors and catalysts in maintaining cell structure and enzymatic processes, such as calcium, phosphate, potassium, magnesium, and iron. Trace elements are necessary for the function of enzymes in the body, including zinc, copper, and selenium[6, 7].

Clinically relevant micronutrient deficiencies that occur over the course of IBD disease progression include anemia (caused by iron, folate, and vitamin B12 deficiencies), bone mineral density loss (due to insufficient calcium, vitamin D, magnesium, and vitamin K levels), impaired thrombosis (caused by folate, vitamin B6, B12 deficiency) and wound healing deficits (due to deficiencies of vitamin A, C, and zinc), and carcinogenesis (related to folate, vitamin D, and calcium deficiency)[6]. Among them, anemia is the most common complication affecting up to 70% of patients with IBD, including UC and CD, and intestinal Behçet’s disease (BD), which is an intestinal invasion of BD with chronic relapsing multisystem vasculitis disorder[12, 13]. Iron deficiency is the most common cause of anemia in 30–90% of patients with IBD, but folate and vitamin B12 deficiencies are also highly prevalent in these patients, especially in those with CD, compared to the general population[14–16]. In addition, bone density is an important factor that affects the quality of life of patients with IBD and disease course of IBD[17, 18]. However, studies assessing micronutrient concentrations in patients with IBD are scarce, and there are currently no studies on micronutrients in patients with intestinal BD, to our knowledge. Therefore, we aimed to investigate the prevalence and risk factors of micronutrient deficiency in patients with IBD and intestinal BD.

Methods

Patients

We conducted a retrospective study of patients with IBD and intestinal BD who underwent laboratory tests to quantify micronutrients such as iron, folate, vitamin B12, and 25-OH-vitamin D from March 2016 to March 2017 at the Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Out of 3,695 patients, a total of 205 with IBD and intestinal BD who underwent micronutrient testing twice were
enrolled retrospectively. A total of 3,490 patients were excluded from our study for the following reasons: (1) patients did not undergo micronutrient testing during the study period (n = 3,047); (2) patients underwent micronutrient blood testing only once (n = 426); (3) data were not available or were lost to follow-up (n = 10); and (4) patients diagnosed with other diseases such as cancer or non-specific inflammation after evaluation (n = 7) (Fig. 1).

We included patients who underwent micronutrient testing at least twice, at baseline and at follow-up after 6 months for one or more of the following four micronutrients: folate (n = 127), vitamin B12 (n = 128), 25-OH-vitamin D (n = 184), and ferritin (n = 97). In addition, we divided patients into two groups: a group consisting of those with a micronutrient deficiency (n = 80) and a non-deficient group (n = 125). This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional review board of Severance Hospital.

**Baseline characteristics**

Variables of baseline characteristics included demographic information, routes of laboratory tests (outpatients or inpatients), medications, supplements, past bowel surgery, and underlying diseases.

**Definitions**

We defined deficient levels of folate and vitamin B12 ascript > 3.38 ng/mL (folate N: 3.38-48.0 ng/mL) and<211 pg/mL (vitamin B12 N: 211–911 pg/mL), respectively. Iron deficiency was defined as ferritin levels <10 ng/mL (N: 10–291 ng/mL). Serum 25-OH-vitamin D testing was performed to identify vitamin D deficiency, with vitamin D deficiency defined as < 10 ng/mL (50 nmol/L).

In our study, the only intestinal surgery associated with diseases of IBD and intestinal BD was limited to bowel operation.

**Statistical analysis**

Variables are expressed as either median (interquartile range, IQR) or n (%). Baseline characteristics were compared using independent Student’s t-tests (or Mann-Whitney tests) for continuous variables, and χ² tests (or Fisher's exact tests) were used for categorical variables, as appropriate. Independent predictors of micronutrient deficiency were analyzed using logistic regression analysis. Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated. Data analysis was performed using Statistical Package for the Social Sciences (SPSS) software (version 20.0; SPSS Inc., Armonk, NY, USA). A P-value < 0.05 was considered statistically significant.

**Results**

**Patient characteristics**

Micronutrient deficiency was observed in 80 (39.0%) of 205 patients who were tested over the year beginning March 2016. Baseline characteristics of the micronutrient deficient and non-deficient groups
were analyzed and are summarized in Table 1. Among the micronutrients assessed, 25-OH-vitamin D was quantified in 90.2% of patients, and vitamin B12, folate and ferritin testings were performed for 47.3–62.4% of patients. In patients with IBD and intestinal BD, folate (80.0% vs. 50.4%; \( P < 0.001 \)), vitamin B12 (80.0% vs. 51.2%; \( P < 0.001 \)), and ferritin deficiencies (60.0% vs. 39.2%; \( P = 0.004 \)) were significantly higher. However, 25-OH-vitamin D deficiency was lower when defined as being < 10 ng/mL (83.8% vs. 94.4%; \( P = 0.013 \)). Patients with CD exhibited a greater prevalence of micronutrient deficiency than those with UC or intestinal BD (82.5% vs. 11.3% vs. 6.3%; \( P = 0.003 \)).
Table 1
Baseline characteristics between micro-nutrient deficiency group and non-deficiency group

| Variables                                | Total (n = 205) | Micro-nutrient deficiency group (n = 80, 39.0%) | Non-deficiency group (n = 125, 61.0%) | P-value |
|------------------------------------------|----------------|-----------------------------------------------|-------------------------------------|---------|
| Male sex                                 | 118 (57.6)     | 44 (55.0)                                     | 74 (59.2)                          | 0.553   |
| Age                                      | 34 (19–47)     | 27 (19–41)                                    | 37 (20–51)                         | 0.003   |
| The path of laboratory test              |                |                                               |                                     | 0.150   |
| Outpatients clinic                       | 191 (93.2)     | 72 (90.0)                                     | 119 (95.2)                         |         |
| Hospitalization patients                 | 14 (6.8)       | 8 (10.0)                                      | 6 (4.8)                            |         |
| Type of micronutrient                    |                |                                               |                                     |         |
| Folate                                   | 127 (62.0)     | 64 (80.0)                                     | 63 (50.4)                          | < 0.001 |
| Vitamin B12                              | 128 (62.4)     | 64 (80.0)                                     | 64 (51.2)                          | < 0.001 |
| 25-OH-vitamin D                          | 184 (90.2)     | 67 (83.8)                                     | 117 (94.4)                         | 0.013   |
| Ferritin                                 | 97 (47.3)      | 48 (60.0)                                     | 49 (39.2)                          | 0.004   |
| Type of IBD                              |                |                                               |                                     | 0.003   |
| UC                                       | 49 (23.9)      | 9 (11.3)                                      | 40 (32.0)                          |         |
| CD                                       | 143 (69.8)     | 66 (82.5)                                     | 77 (61.6)                          |         |

Data are expressed as median (interquartile range, IQR) or n (%). *P-value for comparing patients with micronutrient deficiency group and non-deficiency group.

† Mongersen, vedolizumab; ‡ Myelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, coronary artery occlusive disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, cancer.

IBD, Inflammatory bowel disease; UC, Ulcerative colitis; CD, Crohn's disease; BD, Behçet's disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor; 6-MP, 6-mercaptopurine; SERM, Selective estrogen receptor modulators
| Variables                        | Total (n = 205) | Micro-nutrient deficiency group (n = 80, 39.0%) | Non-deficiency group (n = 125, 61.0%) | P-value |
|---------------------------------|----------------|-----------------------------------------------|-------------------------------------|---------|
| Intestinal BD                   | 13 (6.3)       | 5 (6.3)                                       | 8 (6.4)                             |         |
| Medications                     |                |                                               |                                     |         |
| 5-ASA                           | 114 (55.6)     | 33 (41.3)                                     | 81 (64.8)                           | 0.001   |
| Steroids                        | 12 (5.9)       | 3 (3.8)                                       | 9 (7.2)                             | 0.305   |
| Azathioprine                    | 66 (32.2)      | 32 (40.0)                                     | 34 (27.2)                           | 0.056   |
| Anti-TNF                        | 101 (49.3)     | 45 (56.3)                                     | 56 (44.8)                           | 0.110   |
| Methotrexate                    | 33 (16.1)      | 11 (13.8)                                     | 22 (17.6)                           | 0.464   |
| 6-MP                            | 2 (1.0)        | 0 (0)                                         | 2 (1.6)                             | 0.256   |
| Others†                         | 12 (5.9)       | 2 (2.5)                                       | 10 (8.0)                            | 0.102   |
| Supplementary medications       |                |                                               |                                     |         |
| Iron supplementation            | 77 (37.6)      | 43 (53.8)                                     | 34 (27.2)                           | <0.001  |
| Folate supplementation          | 50 (24.4)      | 26 (32.5)                                     | 24 (19.2)                           | 0.031   |
| Multivitamin                    | 52 (25.4)      | 21 (26.3)                                     | 31 (24.8)                           | 0.816   |
| Calcium, Vitamin D supplementation | 127 (62.0)   | 51 (63.7)                                     | 76 (60.8)                           | 0.671   |

Data are expressed as median (interquartile range, IQR) or n (%). *P*-value for comparing patients with micronutrient deficiency group and non-deficiency group.

† Mongersen, vedolizumab; ‡ Myelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, coronary artery occlusive disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, cancer.

IBD, Inflammatory bowel disease; UC, Ulcerative colitis; CD, Crohn's disease; BD, Behçet's disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor; 6-MP, 6-mercaptopurine; SERM, Selective estrogen receptor modulators
### Table 1: Demographic Characteristics

| Variables                        | Total (n = 205) | Micro-nutrient deficiency group (n = 80, 39.0%) | Non-deficiency group (n = 125, 61.0%) | P-value |
|----------------------------------|----------------|-----------------------------------------------|-------------------------------------|---------|
| Vitamin B12 supplementation      | 43 (21.0)      | 30 (37.5)                                     | 13 (10.4)                          | < 0.001 |
| Vitamin C supplementation        | 3 (1.5)        | 0 (0)                                         | 3 (2.4)                            | 0.163   |
| Zinc supplementation             | 7 (3.4)        | 3 (3.8)                                       | 4 (3.2)                            | 0.832   |
| Osteoporosis medication          |                |                                               |                                     |         |
| SERM                             | 3 (1.5)        | 1 (1.3)                                       | 2 (1.6)                            | 0.839   |
| Bisphosphonate                   | 14 (6.8)       | 1 (1.3)                                       | 13 (10.4)                          | 0.011   |
| Operation                        | 65 (31.7)      | 33 (41.3)                                     | 32 (25.6)                          | 0.019   |
| Hypertension                     | 4 (2.0)        | 1 (1.3)                                       | 3 (2.4)                            | 0.561   |
| Diabetes                         | 1 (0.5)        | 0 (0)                                         | 1 (0.8)                            | 0.423   |
| Osteoporosis                     | 38 (18.5)      | 13 (16.3)                                     | 25 (20.0)                          | 0.500   |
| Others‡                          | 46 (22.4)      | 19 (23.8)                                     | 27 (21.6)                          | 0.719   |

Data are expressed as median (interquartile range, IQR) or n (%). *P*-value for comparing patients with micronutrient deficiency group and non-deficiency group.

† Mongersen, vedolizumab; ‡ Myelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, coronary artery occlusive disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, cancer.

The median age was 34 years [IQR, 19–47], and 57.6% of the enrolled patients were male. In addition, most patients underwent laboratory testing in an outpatient clinic setting compared to an inpatient setting (93.2% vs. 6.8%; P = 0.150). There were no significant differences in most of the types of medications used by patients, but there were significantly more users of 5-aminosalicylic acid (5-ASA) in the non-deficient group (41.3% vs. 64.8%; P = 0.001). Micronutrient deficiency was higher in patients who underwent previous bowel surgery to treat the disease than in those who had not previously undergone disease-related surgery (41.3% vs. 25.6%; P = 0.019) (Table 1)
Relative risk of micronutrient deficiency

Based on the univariate analysis, variables that were significantly associated with micronutrient deficiency included age (OR, 0.975; 95% CI, 0.958–0.993; \( P = 0.006 \)), CD (compared to those with UC or intestinal BD) (OR, 3.810; 95% CI, 1.721–8.430; \( P = 0.001 \)), 5-ASA usage (OR, 0.381; 95% CI, 0.214–0.679; \( P = 0.001 \)), and previous disease-related surgical operations (OR, 2.041; 95% CI, 1.120–3.717; \( P = 0.020 \)) (Table 2). Based on the multivariate analysis assessing variables including male sex, age, the path of laboratory test, types of intestinal disease, medications, previous surgical operations, and other underlying diseases, CD (compared with UC or intestinal BD) (adjusted OR, 2.492; 95% CI, 1.012–6.136; \( P = 0.047 \)) and previous disease-related surgical operations (adjusted OR, 2.714; 95% CI, 1.260–5.844; \( P = 0.011 \)) were identified to be associated with higher risks of micronutrient deficiency. Conversely, age (adjusted OR, 0.973; 95% CI, 0.949–0.998; \( P = 0.037 \)) was negatively associated with micronutrient deficiency (Table 2).
Table 2
Relative risk of micro-nutrient deficiency

| Variable                              | Uni-variate analysis | Multi-variate analysis |
|---------------------------------------|----------------------|------------------------|
|                                       | OR (95% CI)          | P-value                | Adjusted OR (95% CI) | P-value |
| Male sex                              | 0.842 (0.478–1.485)  | 0.553                  | 0.718 (0.375–1.376)  | 0.319   |
| Age                                   | 0.975 (0.958–0.993)  | 0.006                  | 0.973 (0.949–0.998)  | 0.037   |
| The path of laboratory test           |                      |                        |                      |         |
| Outpatients clinic                     | 1.0 (Ref.)           | 1.0 (Ref.)             |                      |         |
| Hospitalization patients               | 2.204 (0.735–6.608)  | 0.158                  | 2.459 (0.715–8.461)  | 0.154   |
| Type of disease                        |                      |                        |                      |         |
| UC                                    | 1.0 (Ref.)           | 1.0 (Ref.)             |                      |         |
| CD                                    | 3.810 (1.721–8.430)  | 0.001                  | 2.492 (1.012–6.136)  | 0.047   |
| Intestinal BD                         | 2.778 (0.734–10.513) | 0.132                  | 1.356 (0.284–6.479)  | 0.703   |
| Medications                            |                      |                        |                      |         |
| 5-ASA                                 | 0.381 (0.214–0.679)  | 0.001                  | 0.548 (0.281–1.068)  | 0.077   |
| Steroids                              | 0.502 (0.132–1.914)  | 0.313                  |                      |         |
| Azathioprine                          | 1.784 (0.983–3.238)  | 0.057                  |                      |         |
| Anti-TNF                              | 1.584 (0.900–2.788)  | 0.111                  |                      |         |
| Methotrexate                          | 0.746 (0.340–1.637)  | 0.465                  |                      |         |
| Others†                               | 0.295 (0.063–1.383)  | 0.121                  |                      |         |
| Operation                             | 2.041 (1.120–3.717)  | 0.020                  | 2.714 (1.260–5.844)  | 0.011   |
| Underlying disease                     |                      |                        |                      |         |
| Hypertension                          | 0.515 (0.053–5.037)  | 0.568                  |                      |         |
| Osteoporosis                          | 0.776 (0.371–1.624)  | 0.501                  | 1.500 (0.699–3.217)  | 0.298   |

† Mongersen, vedolizumab; ‡ Myelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, coronary artery occlusive disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, cancer.

OR, odds ratio; CI, confidence interval; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor
| Variable | Uni-variate analysis | Multi-variate analysis |
|----------|----------------------|-----------------------|
|          | OR (95% CI)          | P-value               | Adjusted OR (95% CI) | P-value |
| Others‡ | 1.131 (0.579–2.206)  | 0.719                 | 2.459 (0.715–8.461)  | 0.154   |

† Mongersen, vedolizumab; ‡ Myelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, coronary artery occlusive disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, cancer.

OR, odds ratio; CI, confidence interval; UC, Ulcerative colitis; CD, Crohn's disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor

Changes in micronutrient levels

Patients with UC and CD had the highest rates of ferritin deficiency compared to the other micronutrients assessed, including vitamin B12, folate, and 25-OH-vitamin D, while in those with intestinal BD, the deficiency did not vary among the micronutrients assessed. However, rates of vitamin B12 deficiency significantly differed among those with UC, CD, and intestinal BD (0% vs. 13.7% vs. 18.2%, respectively; \( P = 0.038 \)) (Fig. 2).

We assessed changes from baseline at the first 6-month follow-up in terms of folate, vitamin B12, 25-OH-vitamin D, and ferritin levels in this study population. Initial laboratory tests in patients with UC showed ferritin and 25-OH-vitamin D deficiency, which had improved at follow-up testing after supplementation. In patients with CD, ferritin, vitamin B12, 25-OH-vitamin D, and folic acid deficiency occurred, and ferritin deficiency was the highest. Patients with intestinal BD had more deficiencies in folic acid and vitamin B12 than ferritin and 25-OH-vitamin D. In all cases, deficiencies were treated at the time of discovery, and after 6 months, all micronutrient deficiencies were reduced (Fig. 3).

Discussion

The study found that micronutrient deficiency was high (39.0%) in patients with IBD and intestinal BD, and 83% of the deficiency group were CD patients. In IBD patients with CD or UC, ferritin deficiency was significant, as was 25-OH-vitamin D deficiency. However, patients with intestinal BD had more folic acid and vitamin B12 deficiencies than those with IBD, who had more ferritin and 25-OH-vitamin D deficiencies. In addition, young age, CD, and intestinal surgery were significantly associated with micronutrient deficiency.

Hwang et al. reviewed studies on micronutrient deficiency in patients with IBD and showed prevalence of micronutrients deficiencies. Among IBD patients, water-soluble vitamins deficiencies have been reported up to 11–78%[16, 19–21]; fat-soluble vitamins deficiencies to 22–90%[19, 21–25]; and macro mineral deficiencies to 36–90%[12, 19, 20, 26–28]. In most studies, patients with CD showed a higher correlation with vitamin or mineral deficiencies than those with UC. Our study also showed a high prevalence (46.2%, 66 of 143 patients) of micronutrient deficiency in patients with CD. Most vitamins and minerals are
absorbed in the proximal small intestine, and vitamin B12 is absorbed in the terminal ileum[6]. The distal ileum is also where bile acid absorption occurs, which is important for the absorption of fat and fat-soluble vitamins[6]. Therefore, micronutrient deficiency should be carefully observed in patients with CD, which is relatively invasive in the small intestine and frequently affects the terminal ileum. In addition, caution should also be exercised in cases of intestinal BD because it often manifests as an oval shape and causes deep ulcers in the ileocecal area[29]. Therefore, patients with intestinal BD also showed micronutrient deficiencies (38.46%, 5 of 13), especially vitamin B12 deficiency; there was a significant difference among patients with UC, CD, and intestinal BD, with the highest prevalence in patients with intestinal BD (UC, 0% vs. CD, 13.7% vs. intestinal BD, 18.2%; \( P = 0.038 \)) (Fig. 2-b). The mostly likely explanation could be due to the location of the intestine affected by the disease, as intestinal BD may be associated with high cobalamin (vitamin B12) deficiency rates.

In patients with IBD, surgery is a significantly important factor affecting the likelihood of micronutrient deficiency. There have been reports of significantly lower vitamin D levels when CD affects the small intestine or when the small intestine is excised[30]. Active Crohn's ileitis and small bowel resection are reported to be risk factors for folic acid deficiency, as they can lead to malabsorption[16, 21]. In addition, Battat et al. reported that ileal resection greater than 30 cm was an associated risk factor for cobalamin deficiency in patients with CD[31]. When further analyzing the risk factors for cobalamin deficiency in our study population, disease-related surgical operation was found to be a significant associated risk factor (OR, 5.513; CI, 1.829–16.613; \( P = 0.002 \); data not shown).

Our study is the first report on micronutrient deficiency in patients with intestinal BD and IBD. However, the study has several limitations. First, it is a retrospective cross-sectional study with selection bias. Because we examined patients who had been tested for a period of 1 year, we could not observe the cumulative effects of time to compare what the deficiencies had been before the start of the study and whether the deficiency occurred again after it ended, even though the deficiencies had been treated. This also showed a limit to the outcome of the assessment of patients with vitamin D deficiency. Even though our study used a lower vitamin D deficiency criterion (< 10 ng/mL) than other studies, many patients were already taking supplements (62.0%), which made it difficult to make a clear comparison. Second, we could not examine the relationship between disease activities. Most were outpatient clinic patients (93.2%), so we could not obtain accurate disease information based solely on the medical records. For example, 55.6% of the included patients were being treated with Pentasa (5-ASA) and 5.9% of patients were treated with steroid medications, suggesting most patients were not in the acute phase of disease progression. Thus, it may have been difficult to clearly compare differences in micronutrient deficiencies among those treated with various medications. Nevertheless, it was found that micronutrient deficiency was high in the outpatient population where the disease activity was not severe.

Conclusions

In conclusion, in patients with IBD and intestinal BD, the incidence of micronutrient deficiency was high (39.0%). In addition, CD, a history of intestinal surgery, and young age were factors significantly
associated with deficiency. Therefore, those with IBD, especially young patients with CD who have undergone bowel resection, should be observed more carefully to assess the need for supplementation to treat micronutrient deficiencies.

**Abbreviations**

IBD, Inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; GI, gastrointestinal; BD, Behçet’s disease; IQR, interquartile range; ORs, Odds ratios; CIs, confidence intervals

**Declarations**

**Ethics approval and consent to participate**

This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional review board of Severance Hospital (2020-1271-001).

**Consent for publication**

The authors consent to the publication policy of the journal.

**Availability of data and materials**

Patient data is kept in a secure place and can only be disclosed to researchers who have been granted access in advance, but cannot be used publicly.

**Competing interests**

The authors declare no conflict of interest.

**Funding**

This study was not funded.

**Acknowledgments**

Soo Jung Park is the guarantor of the article.

**Authors’ contributions**

Conceptualization, PSJ; Methodology, PYE; Software, PYE; Validation, PJJ, CJH, KTI, and KWH; Formal Analysis, PYE; Investigation, PYE; Resources, PYE; Data Curation, PYE; Writing – Original Draft Preparation, PYE; Writing – Review & Editing, PSJ, PJJ, CJH, KTI, and KWH; Visualization, PYE; Supervision, PSJ.

**References**
1. Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intestinal research. 2018;16(1):26–42.

2. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641–57.

3. Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17(3):307–20.

4. Harries AD, Heatley RV. Nutritional disturbances in Crohn's disease. Postgraduate medical journal. 1983;59(697):690–7.

5. Lucendo AJ, De Rezende LC. Importance of nutrition in inflammatory bowel disease. World journal of gastroenterology. 2009;15(17):2081–8.

6. Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. Inflamm Bowel Dis. 2012;18(10):1961–81.

7. Massironi S, Rossi RE, Cavalcoli FA, Della Valle S, Fraquelli M, Conte D. Nutritional deficiencies in inflammatory bowel disease: therapeutic approaches. Clin Nutr. 2013;32(6):904–10.

8. Forbes A, Escher J, Hebuterne X, Klek S, Krznaric Z, Schneider S, Shamir R, Stardelova K, Wierdsma N, Wiskin AE, et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr. 2017;36(2):321–47.

9. Fernandez-Banares F, Abad-Lacruz A, Xiol X, Gine JJ, Dolz C, Cabre E, Esteve M, Gonzalez-Huix F, Gassull MA. Vitamin status in patients with inflammatory bowel disease. Am J Gastroenterol. 1989;84(7):744–8.

10. Headstrom PD, Rulyak SJ, Lee SD. Prevalence of and risk factors for vitamin B(12) deficiency in patients with Crohn's disease. Inflamm Bowel Dis. 2008;14(2):217–23.

11. Hodges P, Gee M, Grace M, Thomson AB. Vitamin and iron intake in patients with Crohn's disease. J Am Diet Assoc. 1984;84(1):52–8.

12. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53(8):1190–7.

13. Kim B, Park SJ, Hong SP, Cheon JH, Kim TI, Kim WH. Overlooked Management and Risk Factors for Anemia in Patients with Intestinal Behcet's Disease in Actual Clinical Practice. Gut Liver. 2015;9(6):750–5.

14. Weisshof R, Chermesh I. Micronutrient deficiencies in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 2015;18(6):576–81.

15. Bermejo F, Algaba A, Guerra I, Chaparro M, De-La-Poza G, Valer P, Piqueras B, Bermejo A, Garcia-Alonso J, Perez MJ, et al. Should we monitor vitamin B12 and folate levels in Crohn's disease patients? Scand J Gastroenterol. 2013;48(11):1272–7.

16. Yakut M, Ustun Y, Kabacam G, Soykan I. Serum vitamin B12 and folate status in patients with inflammatory bowel diseases. European journal of internal medicine. 2010;21(4):320–3.
17. Torki M, Gholamrezaei A, Mirbagher L, Danesh M, Kheiri S, Emami MH. Vitamin D Deficiency Associated with Disease Activity in Patients with Inflammatory Bowel Diseases. Digestive diseases sciences. 2015;60(10):3085–91.

18. Ananthakrishnan AN, Cagan A, Gainer VS, Cai T, Cheng SC, Savova G, Chen P, Szolovits P, Xia Z, De Jager PL, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis. 2013;19(9):1921–7.

19. Filippi J, Al-Jaouni R, Wiroth JB, Hebuterne X, Schneider SM. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis. 2006;12(3):185–91.

20. Vagianos K, Bector S, McConnell J, Bernstein CN. Nutrition assessment of patients with inflammatory bowel disease. JPEN Journal of parenteral enteral nutrition. 2007;31(4):311–9.

21. Vagianos K, Bernstein CN. Homocysteinemia and B vitamin status among adult patients with inflammatory bowel disease: a one-year prospective follow-up study. Inflamm Bowel Dis. 2012;18(4):718–24.

22. Siffledeen JS, Siminoski K, Steinhart H, Greenberg G, Fedorak RN. The frequency of vitamin D deficiency in adults with Crohn's disease. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2003;17(8):473–8.

23. Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr. 2002;76(5):1077–81.

24. Leslie WD, Miller N, Rogala L, Bernstein CN. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol. 2008;103(6):1451–9.

25. Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr. 2006;60(7):889–96.

26. Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(8):797–813.

27. Bernstein CN. Inflammatory bowel diseases as secondary causes of osteoporosis. Curr Osteoporos Rep. 2006;4(3):116–23.

28. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006;24(11–12):1507–23.

29. Lee HJ, Cheon JH. Optimal diagnosis and disease activity monitoring of intestinal Behcet's disease. Intestinal research. 2017;15(3):311–7.

30. Schaffler H, Schmidt M, Huth A, Reiner J, Glass A, Lamprecht G. Clinical factors are associated with vitamin D levels in IBD patients: A retrospective analysis. Journal of digestive diseases. 2018;19(1):24–32.

31. Battat R, Kopylov U, Szilagyi A, Saxena A, Rosenblatt DS, Warner M, Bessissow T, Seidman E, Bitton A. Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management. Inflamm Bowel Dis. 2014;20(6):1120–8.